Can incretins ease psoriasis inflammation?

On 16 August 2026, the journal Expert Opinion on Biological Therapy published an editorial by Eva Klara Merzel Šabović, of the Dermatovenerology Clinic, and Miodrag Janić, of the Clinical Department of Endocrinology, Diabetes and Metabolic Diseases, both at University Medical Centre Ljubljana, asking whether incretin therapy could be "the missing link" to silencing residual inflammation in psoriasis patients already treated with a biologic^[1]. It is an editorial, not a completed trial. The authors are posing a question for the field to test, not reporting a result, and the distinction matters for anyone deciding what to do with this.

What 'residual inflammation' means for a psoriasis patient on a biologic

Biologics that target interleukin-17, interleukin-23 or tumour necrosis factor now clear the skin to a PASI 90 or PASI 100 response for a large share of patients. But those drugs act on specific inflammatory pathways in skin and joints. They were never designed to address the broader cardiometabolic inflammation that tracks alongside psoriasis independently of skin severity: patients with psoriasis carry disproportionate rates of obesity, type-2 diabetes and cardiovascular disease compared with the general population, and clearing the rash does not necessarily clear that burden. That gap between skin clearance and systemic risk is the "residual inflammation" the editorial's title refers to.

Why tirzepatide specifically, not the GLP-1 class in general

The editorial's own keyword index does not just list glucagon-like peptide-1 (GLP-1) receptor agonists generically. It names tirzepatide, the dual GIP and GLP-1 receptor agonist marketed as Mounjaro and Zepbound, alongside visceral adiposity, biologic therapy and residual inflammation^[1]. That framing points to a specific hypothesis: that a drug with a larger effect on visceral fat and weight than earlier incretin mimetics might do more to quiet the metabolic-inflammation component of psoriasis than the class did when it was tested a decade ago with weaker, older molecules.

The real-world signal that exists: fewer cardiovascular events, not less skin disease

The strongest data available right now on GLP-1 receptor agonists and psoriasis is not about skin at all. Olbrich and colleagues published a large retrospective cohort study in the British Journal of Dermatology in 2026, using the US TriNetX database to compare 3,048 psoriasis patients treated with a GLP-1 receptor agonist against matched patients on other antidiabetic or antiobesity medications over two years^[2]. GLP-1RA treatment was associated with significantly lower all-cause mortality and fewer cardiovascular events, with the reduction more pronounced in the psoriasis population than in matched patients without psoriasis, and without an increase in typical adverse drug events. That is a real signal, and it lines up with the comorbidity argument above. It is not, however, a measurement of psoriasis severity, PASI score, or skin-level inflammation. It tells you incretin therapy may be good for the whole patient. It does not by itself tell you it quiets the disease on the skin.

What the skin-specific trial evidence actually shows

The one randomised, placebo-controlled trial that tested a GLP-1 receptor agonist directly against psoriasis severity found no benefit on the skin. Faurschou and colleagues, in a 2015 trial published in the Journal of the European Academy of Dermatology and Venereology, gave 20 obese, glucose-tolerant adults with plaque psoriasis either liraglutide or placebo for eight weeks^[3]. Liraglutide, an older GLP-1 receptor agonist in the same class as semaglutide and tirzepatide, produced significantly more weight loss than placebo (4.7 kg versus 1.6 kg) and better cholesterol numbers. But PASI scores fell by a similar amount in both arms (-2.6 on liraglutide versus -1.3 on placebo, not a statistically significant difference), and dermatology-life-quality scores and inflammation markers were unchanged between groups. Weight loss on an incretin drug did not translate into measurably less psoriasis in that trial.

What the editorial is not

It is not a clinical trial of tirzepatide added on top of a biologic in psoriasis. It is not new laboratory or biomarker data on residual inflammation. It is an expert-opinion piece, the kind a journal commissions to argue a case and prompt further research, written by a dermatologist and an endocrinologist reading across two literatures that do not usually talk to each other. A search of ClinicalTrials.gov in August 2026 turned up no registered trial testing an incretin therapy added on top of a biologic specifically for psoriasis. If one gets designed on the back of this editorial, that is the study that would actually answer the question the title asks.

Why this matters

Psoriasis patients on an effective biologic can still be walking around with elevated cardiometabolic risk that the biologic never touched. Whether an incretin therapy like tirzepatide or semaglutide genuinely quiets that residual inflammation, on top of treating the weight and metabolic disease it is already approved for, is an open, testable question rather than a settled finding. The one skin-specific RCT that exists found no PASI benefit with an older, weaker molecule. The one large real-world dataset found a mortality and cardiovascular benefit but did not measure skin. Until a trial closes that gap directly, this stays a hypothesis worth watching, not a reason to add a GLP-1 drug to a psoriasis regimen for the skin itself. That conversation, like any change to a psoriasis or metabolic treatment plan, belongs with the prescribing dermatologist and, where relevant, an endocrinologist.